Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

 Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.

https://generics.pharmaintelligence.informa.com/GB151399/Viatris-Believes-Eylea-Biosimilar-Candidate-Is-First-To-Reach-US-FDAs-Desk